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Abstract We conducted a longitudinal and cross-sectional
analysis of depressive symptomology in iPrEx, a random-
ized, placebo-controlled trial of daily, oral FTC/TDF HIV
pre-exposure prophylaxis (PrEP) in men and transgender
women who have sex with men. Depression-related adverse
events (AEs) were the most frequently reported severe or
life-threatening AEs and were not associated with being
randomized to the FTC/TDF arm (152 vs. 144 respectively
OR 0.66 95 % CI 0.35–1.25). Center for Epidemiologic
Studies Depression scale (CES-D) and a four questions sui-
cidal ideation scale scores did not differ by arm. Participants
reporting forced sex at anal sexual debut had higher CES-D
scores (coeff: 3.23; 95 % CI 1.24–5.23) and were more likely
to have suicidal ideation (OR 2.2; 95 % CI 1.09–4.26). CES-
D scores were higher among people reporting non-condom
receptive anal intercourse (ncRAI) (OR 1.46; 95 % CI
1.09–1.94). We recommend continuing PrEP during periods
of depression in conjunction with provision of mental health
services.
Resumen Llevamos a cabo un ana´lisis logitudinal y
transversal de la sintomatologia depresiva en iPrEx, del
estudio de placebo controlado, con seleccion de brazo al
azar. Involucra tratamiento oral diario de FTC/TDF que
esta usado como quimoprofilaxis de pre-exposicion (PrEP)
contra VIH en hombres y mujeres transge´nero que tienen
relaciones sexuales con hombres (MSM/TGW). Eventos
relacionados a depresion (AEs) fueron reportados como los
sintomas mas adversos o de riesgo de vida. Estos no fueron
asociados con la seleccion al azar del brazo FTC/TDF (152
contra 144 respectivamente; OR: 0.66; 95 % CI: 0.35-
1.25). La escala de depresion (CES-D), que proviene del
centro de Estudios Epidemiolo´gicos de Depresion y un
‘‘filtro’’ con cuatro preguntas para detectar suicidios con-
templados no difirieron entre los brazos. Personas que
reportaron ser forzados tener sexo, siendo su primer
encuentro con sexo anal, tenian CES-D resultados mas
altos (Coeff: 3.23; 95 % CI: 1.24 a 5.23) y fueron mas
probable contemplar suicidio (OR 2.2; 95 % CI: 1.09 a
4.26). CES-D resultados fueron mas altos en personas
reportando recibir penetracion anal sin condon (ncRAI)
(OR: 1.46; 95 % CI: 1.09 a 1.94). Recomendamos conti-
nuar PrEP durante periodos de depresion, mientras simul-
taneamente recibir servicios de salud mental.
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HIV prevention  PrEP  FTC/TDF  iPrEx
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Introduction
Depression is a highly prevalent condition that presents
with psychological, behavioral, and physical symptoms
that can be debilitating, interfere with self-care, influence
social interactions, and lead to suicide [1]. Depression is
the second leading cause of disability worldwide [2].
Studies conducted in the United States suggest that the
prevalence of depression is substantially higher among men
and transgender women who have sex with men (MSM/
TGW) compared to men in the general population [3–5].
Population-based mental health surveys have found higher
rates of major depression; anxiety; substance use; childhood
emotional, sexual and physical mistreatment; and suicidal
behaviors in individuals disclosing same-sex sexual behav-
iors or identifying as gay [3, 6–9]. In addition, MSM/TGW
carry a disproportionate burden of the HIV epidemic, and
contend with victimization, harassment, rejection and fear of
rejection, and discrimination [10, 11]. Psychosocial health
problems, including depression, increase risk for HIV
acquisition via sexual practices [8, 12, 13], however the
effects of depression on HIV acquisition may differ
depending on depression severity. The EXPLORE study
found a curvilinear relationship between the severity of
depression and sexual risk taking in African–American
MSM in the US, whereby moderately depressed individuals
reported the most risky sexual behaviors compared to non-
depressed or severely depressed individuals [14]. Childhood
sexual abuse (CSA) in MSM/TGW has also been identified
as a factor strongly associated with increased risk for HIV
acquisition [15, 16]. History of CSA in MSM/TGW is
associated with an increased likelihood of engaging in sexual
behaviors that put them at risk for HIV infection [15].
Daily, oral Truvada (a coformulation of emtricitabine
and tenofovir disoproxil fumarate, or FTC/TDF) is safe and
effective for HIV pre-exposure prophylaxis (PrEP) [17–20].
The iPrEx study was a multinational, randomized, placebo-
controlled trial that investigated the safety and efficacy of
FTC/TDF PrEP in a cohort of MSM/TGW. Depression was
one of the most frequently reported adverse events (AEs) in
the study [18]. Previous studies of antiretroviral therapies
(ARTs), including FTC and TDF in HIV-infected partici-
pants have reported high rates of depression-related AEs and
raised concerns regarding the possible influence of these
antiretroviral regimens on depression [21–23]. While sub-
sequent studies have reported that efavirenz shows the
strongest association with mental health diagnoses [24], the
prescribing information and medication guide for FTC/TDF
includes depression as a potential AE in HIV-infected indi-
viduals. Previous studies have not examined the effect of
FTC/TDF on depression in absence of other ARTs or outside
of the context of HIV infection. The iPrEx study presented a
unique opportunity to look at the impact of FTC/TDF
specifically on depression in a randomized manner in HIV-
uninfected individuals.
As FTC/TDF for PrEP becomes increasingly popular, it
is important to understand the role of depression in HIV
acquisition risk and if PrEP affects depression. This anal-
ysis addresses these questions with three primary aims in
the iPrEx cohort: (1) determine if FTC/TDF is associated
with depression (compared to placebo), (2) describe the
prevalence of and the risk factors for depression, and (3)
examine how depression may be associated with sexual
practices. These findings will be important in establishing
the safety profile of FTC/TDF PrEP in HIV-uninfected
MSM/TGW at risk for depression, and in understanding
how depression may impact the risk of acquiring HIV in
these populations.
Methods
Study Overview and Population
Details of the iPrEx clinical trial have been published
elsewhere [18]. In brief, MSM/TGW were randomized to
receive daily oral FTC/TDF or placebo plus a compre-
hensive package of prevention services, and were followed
for HIV infection and safety outcomes. The trial was
conducted in 9 cities around the world (San Francisco and
Boston, United States; Cape Town, South Africa; Chang
Mai, Thailand; Lima and Iquitos, Peru; Guayaquil, Ecua-
dor; and Rio de Janeiro and Sa˜o Paulo, Brazil).
The inclusion criteria were male at birth, at least
18 years old, HIV seronegative, and reporting sexual
practices conferring risk for acquisition of HIV. Study
visits occurred every 4 weeks and included rapid HIV
antibody testing, adherence counseling, pill count, drug
dispensation, and medical history. Computer-Assisted Self
Interviews (CASI), administered at the screening and
quarterly visits, collected information about demographics,
drug and alcohol use, sexual practices, and behavioral risk
factors. Information about sexual practices was also col-
lected quarterly using an interviewer-administered ques-
tionnaire. Study details are available in the supplemental
materials of the original report [18]. The iPrEx cohort
enrolled 2,499 subjects; 83 % were enrolled in Latin
America. The age of participants ranged from 18 to
67 years (mean 24 years), and the baseline characteristics
of the two study arms (placebo and FTC/TDF) were sim-
ilar. Participants provided written informed consent for all
study procedures, which were conducted in accordance
with the Institutional Review Board (IRB) guidelines at
each participating institution.
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Measures
Depression and Suicide Adverse Events
Clinicians assessed AEs, including depression, every
4 weeks through the end of study follow-up. AEs that were
grade 2 or higher, as determined by the DAIDS Table for
Grading the Severity of Adult and Pediatric AEs Version
1.0, December, 2004 (clarification August 2009), all bone
fractures, and all creatinine elevations were recorded on
Case Report Forms (CRFs) and faxed to the study data
management center (DF/Net Research Inc.). Staff trained
in MedDRA coding followed the conventions outlined in
the MedDRA Term Selection Points to Consider Document
(release 3.8 based on MedDRA version 10.0) to code all
reported AEs. The preferred MedDRA terms for depression
AEs used in this study were ‘‘Depression’’, ‘‘Depressed
Mood’’, ‘‘Depression suicidal’’, ‘Major Depression’’,
‘‘Suicidal Ideation’’, ‘‘Suicide Attempt’’, ‘‘Adjustment
Disorder’’, and ‘‘Adjustment Disorder with Mixed Anxiety
and Depressed Mood’’.
CES-D and Suicidal Ideation Screeners
Depressive symptoms were assessed at screening and at
semi-annual visits using the widely used 20-item Center for
Epidemiologic Studies Depression Scale (CES-D) vali-
dated in English, Spanish, Portuguese and Thai [25–30].
The CES-D is both valid and reliable as a screening tool for
depressive symptomatology and provides an estimate of
depressive symptom prevalence within a study population
rather than a clinical diagnosis of depression [25, 26, 31].
In addition, since the CES-D has no items on suicide, a
4-item suicide ideation survey screener was also imple-
mented. The 4 items of this screener were ‘‘I had thoughts
about death’’, ‘‘I thought about killing myself’’, ‘‘I felt my
family and friends would be better off if I were dead’’ and
‘‘I felt that I would kill myself if I knew a way’’. An item
endorsed as occurring ‘‘rarely or none of the time’’ was
assigned a value of 1, ‘‘some or little of the time’’ was
assigned 2, ‘‘occasionally or a moderate amount of the
time’’ was assigned a 3 and ‘‘most or all of the time’’ was
assigned a 4. The values for each of the items were com-
puted (with a possible range between 4 and 16) [30, 32].
For aims 1 and 2 in which depression is the outcome of
interest, CES-D scores (range 0–60) were analyzed contin-
uously. For aim 3, in which depression is examined as a
predictor of sexual practices, the CES-D scores were cate-
gorized for more meaningful interpretation of results. Pre-
vious studies of US MSM have categorized CES-D either
dichotomously with CES-D scores C16 representing clini-
cally significant depressive symptoms and CES-D scores
\16 as absence of symptoms; or with 16–26 for moderate
versus C27 for severe depressive symptoms [12, 33, 34].
However, given that the distribution of CES-D scores can
vary across cultures, we chose to categorize CES-D scores by
quartiles observed in our multi-cultural study population
(CES-D B 7; 7\CES-D B 12; 12\CES-D B 19; CES-
D[ 19) [12, 35]. For all analyses, suicide ideation scores
were analyzed as a dichotomous variable indicating presence
or absence of suicidal ideation, as defined by a score of 3 or
greater on any individual item of the suicide ideation scale
[30, 32].
At the time of the design and initiation of the iPrEx
study in 2006–2007, depression screening instruments were
not routinely used in prevention clinical trials. However, in
July of 2009, motivated by the occurrence of 46 depres-
sion-related AEs in 41 individuals in addition to two sui-
cide attempts, the study team incorporated the regular
administration the CES-D and the suicide ideation screener
to the study protocol. All participants who screened as
having depressive symptoms or suicidal ideation received
mental health assessments at the study site, and, in some
cases, referrals for off-site psychiatric evaluations and
follow-up. Not all sites were able to provide outside
referrals because of the paucity of locally available mental
health services. Implementation of these new study pro-
cedures occurred at each site depending on the local IRB
review timelines. Given that most iPrEx participants
enrolled in iPrEx prior to July 2009, CES-D scores from
screening visits are missing for many participants. In cases
of seroconversion, all CES-D collected after the serocon-
version time points were excluded from our analyses.
FTC/TDF Drug Exposure
Drug levels were assessed using FTC and tenofovir (TFV)
in blood plasma, and their active metabolites, FTC-
triphosphate (FTC-TP) and TFV-diphosphate (TFV-DP) in
viably cryopreserved peripheral blood mononuclear cells
(PMBCs), by liquid chromatography/tandem mass spec-
trometry [36]. The drug detection variable of TFV-DP was
categorized as: 0—below the level of quantitation; 1—drug
detected B16 fmol/106 cells; 2—drug detected[16 fmol/
106 cells using the previously established cut-off which is
the intracellular concentration TFV-DP associated with a
90 % reduction in HIV acquisition relative to the placebo
arm, in presence of FTC [36].
Predictors of Depressive Symptoms
Demographic covariates including age, race, ethnicity,
alcohol consumption, and study site were collected from
CRFs and CASI questionnaires at baseline. ‘‘Trans’’
identity was defined as self-identifying as either ‘‘trans’’ or
‘‘a woman’’ on the CASI questionnaire.
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To explore the potential relationship between trauma
and subsequent depression, we selected behavioral char-
acteristics from the screening CASI that may reflect prior
traumatic experiences. The characteristics analyzed were
‘‘fear of violence’’, concern surrounding ‘‘acceptance
amongst family members’’, and history of ‘‘forced sex’’.
‘‘Forced sex’’ was defined as having reported being
‘‘forced’’ or ‘‘manipulated’’ at time of anal sexual debut.
Sexual Practices
Participants were asked about their sexual practices over
the past three months at screening and at each quarterly
visit during an interview-administered questionnaire.
Measures used for this analysis were: the total number of
anal sex partners, the number of partners with whom par-
ticipants reported non-condom receptive anal intercourse
(ncRAI), and the number of partnerships when a condom
was used. Reported sexual behavior was recoded to create a
binary variable for any ncRAI.
Statistical Analyses
All analyses were performed in STATA 13.1 (StataCorp,
College Station, TX, USA).
Aim 1: Is FTC/TDF Associated with Depression
in the iPrEx Cohort?
To minimize the potential bias caused by the late intro-
duction of the CES-D screener, the primary analysis
examined depression AEs by study arm. The number of
individuals with depression AEs was compared in the FTC/
TDF and placebo arm. A v2 test was used to test for dif-
ferences by arm. To compare the total number of depres-
sion AE events by arm, a mixed-level random effects
logistic regression was performed that accounts for clus-
tering by participant.
The secondary analysis looked at changes in depressive
symptomology that may not have had a clinical manifes-
tation by exploring the effect of randomization on CES-D
scores. A generalized estimating equation model was used
to look at the effect of randomization on CES-D scores
throughout the course of study follow-up. Similarly, a
mixed level logistic regression model was used to test the
effect of randomization on the presence of suicidal ideation
as measured by the suicidal screener.
To ensure that any effects of FTC/TDF on depression
were not obscured by imperfect adherence to the study
drug, an as-treated analysis was conducted using drug
detection in PBMCs. Age, study site, and anti-depressant
medication use were considered as potential confounders
and included in the model.
Aim 2: Predictors of Depression in the iPrEx Cohort
Multilevel linear and logistic regressions clustering on study
site and participant were used to examine the effect of
demographics and childhood traumatic events on depressive
symptoms and presence of suicidal ideation respectively.
Aim 3: Does Depression Influence Sexual Practices
in the iPrEx Cohort?
Multivariate logistic regression was performed to explore
associations between CES-D scores and reported ncRAI,
the major risk factor for HIV acquisition in this cohort [37]
while controlling for total number of partners, age, anti-
depressant medication use and study site. The first avail-
able CES-D score and corresponding sexual behavior data
were used.
Missing Data and Sensitivity Analyses
Missing CES-D
In order to understand the potential effect of excluding
those who never received a CES-D assessment as a result
of delayed implementation, we compared baseline demo-
graphics and depression as a pre-existing condition
between those who had a CES-D assessment and those that
did not using multivariate logistic regression.
Additionally, to assess for potential selection bias, we
explored whether or not depression or depressive symp-
toms show any evidence of increasing the rate of study
drop out using a cox proportional hazards model.
Missing Drug Levels
Multiple imputation was used to fill in the randomly
missing data for time points at which drug levels were not
directly measured as described previously [36].
Results
Is FTC/TDF Associated with Depression
in the iPrEx Cohort?
Depression AEs by Study Arm
Depression was the most frequently reported severe or life-
threatening AE in the iPrEx trial [18]. There were a total of
296 depression-related AEs during follow-up. Suicidal
ideation and attempts were considered grade 4 (life-
threatening) AEs. Table 1 compares depression-related
AEs between study arms. There were no significant
AIDS Behav (2016) 20:1478–1488 1481
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differences between arms (active vs FTC/TDF) in number
of participants reporting depression-related AEs (OR 0.81;
95 % CI 0.62–1.06), the absolute number of depression
AEs (OR 0.66; 95 % CI 0.35–1.25), or grade 4 AEs (OR
0.5; 95 % CI 0.22–1.15).
There were 36 suicide attempts or gestures during the
study: 16 in the placebo arm, and 20 in the FTC/TDF arm
(OR 1.26 95 % CI 0.65–2.43). There was no suicide.
Attempts included ingestions of poisons or overdose of
medications. Eight medication ingestions involved study
drug, four of which occurred in the FTC/TDF arm and
could have involved as few as two tablets or as many as 30
tablets, either alone or in combination with other medica-
tions. No clinical AEs were associated with these over-
doses. The serum creatinine remained normal in all cases.
The protocol required that study drug be discontinued
for grade 4 depression-related AEs. As any suicidal idea-
tion is defined as a grade 4 AE, 75 depression-related AEs
led to study drug discontinuation; of which 36 (49 %) were
permanent and 38 (51 %) were temporary lasting
0.5–6.4 months. Three participants became HIV infected
while being on one of these interruptions in study medi-
cation that were mandated by the protocol.
CES-D and Suicide Screening Scores by Study Arm
Overall, 2,131 of 2499 (85 %) enrolled participants com-
pleted at least one CES-D (1423 Spanish, 318 Portuguese,
267 English, and 107 Thai). CES-D completion was
comparable in both study arms (1,076 placebo; 1055 FTC/
TDF). Mean duration of study participation prior to com-
pleting a CES-D was 15 months (IQR 11–22 months).
Most participants were between 18 and 24 years of age and
identified as Hispanic/Latino ethnicity, with Spanish as
their main language. Over 2/3 of the cohort had completed
secondary education. For participants for whom a CES-D
was available, the mean number of sex partners in the past
3 months at baseline was 18 partners, and 61 % of par-
ticipants reported ncRAI in the past 3 months.
Table 1 depicts results of the generalized estimating
equation and multilevel logistic regression indicating no dif-
ference in CES-D scores or suicidal ideation respectively by
study arm. Median CES-D score was 12 and approximately
8 % of the cohort tested positive on the suicide ideation
screener, regardless of study arm.
381 participants did not complete a CES-D, most of
whom exited the study before the CES-D was implemented.
The study baseline characteristics of participants for whom a
CES-D was available were not substantially different than of
those participants for whom a CES-D was unavailable with
respect to race, ethnic group, education, site, alcohol use,
and sexual practices at screening (Table 2). Mean age for
participants who did not complete a CES-D was 1.6 years
younger than those who completed at least one questionnaire
(95 % CI 0.72–2.67), reflecting the younger average age of
the Andean study sites participants.
For participants for whom we had CES-D scores avail-
able, higher CES-D scores were not associated with a
greater hazard of dropping out of the study early (HR 0.92;
95 % CI 0.70–1.21). Additionally, the proportion having
depression as a pre-existing condition was higher amongst
those with at least one CES-D measurement than amongst
those excluded from the analysis (6.29 vs. 2.45 % respec-
tively; p = 0.11 after controlling for study site).
Table 1 Depression-related clinical AEs, CES-D scores and number of participants who screened positive for suicidal ideation in iPrEx by study
arm
Placebo n (%)e FTC/TDF n (%) OR/
Coeffb
95 % CI
Number of participants reporting depression-related AEs (grade 2 or higher)a 127 (10.18) 105 (8.37) 0.81 [0.62 to 1.06]
Number of depression-related AEs (grade 2 or higher)a 152 (51.35) 144 (48.65) 0.66 [0.35 to 1.25]
Number of grade 4 depression-related AEsa 53 (34.87) 40 (27.78) 0.5 [0.22 to 1.15]
CES-D score 12c 12c 0.2b [-0.46 to 0.86]
Number of participants who screened positive for suicidal ideationd 250 (8.29) 230 (7.83) 0.9 [0.67 to 1.21]
AE Adverse Event, CES-D Center for Epidemiologic Studies Depression Scale, FTC/TDF emtricitabine tenofovir disoproxil fumarate, OR odds
ratio, 95 % CI confidence interval, Coeff coefficient
a Clinical AEs, as defined by the NIH DAIDS Table for Grading the Severity of Adult and Pediatric AEs Version 1.0, December, 2004
(Clarification August 2009) http://rsc.tech-res.com/safetyandpharmacovigilance
b Linear regression coefficient
c Median CES-D score
d Positive for suicidal ideation is defined as a score C3 on any of the four questions in the suicide ideation screener
e Percentages refer to either % of total number participants, or % of total number of events
1482 AIDS Behav (2016) 20:1478–1488
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As-treated Analyses
The multilevel mixed effects linear regression using mul-
tiple imputed drug data showed no significant association
between drug exposure and CES-D scores (Coeff. -0.23;
95 % CI -2.23 to 1.76) or suicidal ideation (OR 1.18;
95 % CI 0.58–2.41) after controlling for anti-depressant
medication use, age, and site.
Predictors of Depression
The mean CES-D score of the entire cohort was 14 (range
0–55). Table 3 presents the demographic characteristics and
childhood risk factors for depressive symptomology. The
multilevel mixed effects linear regression controlling for
clustering on study site and study participant indicates that
having reported forced sex at anal debut and identifying as
TGW are significantly associated with higher CES-D scores
on average. Younger participants also trended towards
higher CES-D scores than the older participants.
When examining suicidal ideation as the outcome in a
multivariate mixed level logistic regression, participants
reporting forced sex also had 2.2 times the odds of having
suicidal ideation than participants not reporting forced sex
at anal debut (95 % CI 1.31–5.53). Additionally, black or
African American participants had 2.15 times the odds of
reporting suicidal ideation compared to participants of
mixed/other race (95 % CI 1.09–4.26). No other variables
were important predictors for suicidal ideation.
Does Depression Influence Sexual Practices
in the iPrEx Cohort?
Table 4 shows the effect of depressive symptomology on
sexual behaviors. After adjustment for age, study site, anti-
depressant medication use, and number of partners, par-
ticipants in the highest quartile of CES-D scores had
greater odds of reporting ncRAI in the past 3 months than
those in the lowest quartile of CES-D. None of the other
sexual exposures measures were associated with CES-D
scores.
Anti-depressant Medication Use
Use of anti-depressant medication at any time during study
observation was reported in 211 (8.4 %) participants
overall and there were no differences in anti-depressant
medication use between study arms (8.6 % placebo vs
8.2 % FTC/TDF arm; Wilcoxon rank-sum z: 0.38
p = 0.71). Antidepressant use at any time during the study
was reported by 50 % of participants with depression-re-
lated grade 2 ? AEs.
Discussion
During the iPrEx trial, daily oral FTC/TDF PrEP was not
associated with depression; there were no significant dif-
ferences in total number of depression-related AEs, CES-D
scores, or suicidal ideation scores between study arms. As-
treated analyses confirmed these findings, ruling out that
similarity between groups could be attributable to lack of
detectable drug exposure. Depression had been previously
observed in trials of HIV-infected MSM receiving FTC/
TDF in combination with other drugs for HIV treatment
[21–23]. Antiretroviral medications used with FTC/TDF in
Table 2 Demographic characteristics of iPrEx participants with at
least one CES-D questionnaire (n = 2115) and without (n = 381)a
CESD available No CESD
N = 2115 N = 381
Age (mean) 27.4 25.8
Race n (%)
Black/African–American 180 (8.4) 34 (9.2)
White 372 (17.5) 61 (16.6)
Mixed/other 1458 (68.4) 263 (71.5)
Asian 121 (5.7) 10 (2.7)
Ethnic group n (%)
Hispanic/Latino 1517 (71.2) 288 (78.3)
Non-Hispanic/Latino 614 (28.8) 80 (21.7)
Education n (%)
Less than secondary 440 (20.6) 84 (22.8)
Completed secondary 743 (34.9) 141 (38.3)
Post-secondary 928 (43.5) 136 (37.0)
Region n (%)
Brazil 318 (14.9) 52 (14.1)
Andes 1423 (66.8) 277 (75.3)
United States 209 (9.8) 18 (4.9)
South Africa 72 (3.4) 16 (4.3)
Thailand 109 (5.1) 5 (1.4)
No. of alcoholic drinks n (%)b
0–4 per day 992 (46.5) 139 (36.5)
C5 per day 772 (36.2) 159 (41.7)
Sexual practices at screening n (%)
Number of partners in the
past 12 months (mean)
16 21
Any non-condom receptive
anal intercourse (ncRAI) in
the past 12 weeks
1288 (60.4) 197 (53.5)
Any transactional sex in
the past 24 weeks
848 (39.8) 179 (48.6)
a Some categories do not add up to 100 % due to no answers/missing
responses. Three participants had questionnaires that were largely
incomplete and therefore not used for this analysis
b On days subject drank in the past 4 weeks
AIDS Behav (2016) 20:1478–1488 1483
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Table 3 Predictors of depressive symptomology in 2,115 MSM/TGW iPrEx participants for which at least one CES-D was availablea,b
Na Median CESDb Coeffc 95 % CIc
Race
Mixed/other 1458 12 ref.
Black/African American 180 12 0.37 [-1.33, 2.07]
White 372 11 -0.88 [-2.16, 0.41]
Asian 121 12.5 -0.75 [-2.83, 1.34]
Hispanic ethnicity
Not Hispanic/Latino 614 12 ref
Hispanic/Latino 1517 12 -0.59 [-1.89, 0.71]
Age
18–24 1049 12 1.25 [-0.07, 2.57]
25–29 439 12 0.95 [-0.47, 2.37]
30–39 404 12 1.06 [-0.35, 2.47]
C40 239 12 ref.
Forced Sexd
No 2000 12 ref.
Yes 83 15 3.23 [1.24, 5.23]
Alcohole
0–4 per day 982 12 ref.
C5 per day 770 12 0.36 [-0.43 to 1.17]
Education
\Secondary School 440 13 ref.
Secondary School 743 12 -0.29 [-1.37, 0.79]
Post-Secondary School 928 12 -0.4 [-145, 0.66]
‘‘Trans’’ Identityf
No 1863 12 ref.
Yes 268 13 1.22 [0.51, 2.40]
Study Site (country)
Praca Onze (BRA) 83 12
USP (BRA) 66 12
Fiocruz (BRA) 169 12
INMENSA (PER) 759 13
ACSA (PER) 413 12
Equidad (ECU) 251 12
San Francisco (USA) 131 9
Boston (USA) 78 10.5
Cape Town (ZFA) 72 12
Chiang Mai (THA) 109 13
Country codes: BRA Brazil, PER Peru, ECU Ecuador, USA United States, ZFA South Africa, THA Thailand
CES-D scores measured after seroconversion were excluded from analysis
Multivariate analyses show that reporting forced sex at anal debut and reporting ‘‘trans’’ identity were the only baseline characteristics
significantly associated with an increase in CES-D scores when controlling for all other covariates
AE Adverse Event, CES-D Center for Epidemiologic Studies Depression Scale, OR Odds Ratio, 95 % CI confidence interval, Coeff coefficient
a Number of participants
b Median CES-D scores including all time points at which a CES-D was available (multiple observations per person)
c Results of multilevel mixed model with random effects for site and participant
d Forced sex is defined as having reported being ‘‘manipulated’’ or ‘‘forced’’ at the time of anal sex debut, as recorded in the CASI questionnaire
e On days when alcohol was used in the past 30 days prior to baseline characteristics were collected
f ‘‘Trans’’ identity is defined as self-identifying as ‘‘trans’’ or ‘‘a woman’’ on the screening visit CASI questionnaire
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these studies included efavirenz, which could have been
responsible for these observations [38, 39]. In fact, recent
evidence has linked efavirenz to neuropsychiatric effects
and mental health diagnoses, including suicidal ideation,
attempts or completion [24].
Though not related to oral FTC/TDF PrEP use,
depression was one of the major AEs reported in iPrEx.
Half of iPrEx participants who completed at least one CES-
D had scores greater than or equal to 16 at some point over
the course of the study, which is the cut-off considered to
reflect clinically significant depressive symptoms in some
settings [12, 26, 33]. In the iPrEx cohort, having been
forced to have sex at anal sexual debut and ncRAI was
associated with higher CES-D scores and there were trends
toward higher scores among younger people and TGW.
Our observations are consistent with previous findings that
depressive symptoms are common in MSM/TGW, espe-
cially young people and those who identify as transgender
women [10, 40]. MSM/TGW are at increased risk for
social isolation, history of childhood abuse (including
sexual abuse), and ongoing discrimination, which increase
vulnerability to depression and suicide [6, 7, 9]. On the
other hand, in this analysis, we did not see an association
between alcohol use and CES-D scores. In-depth analyses
of substance and alcohol use in iPrEx, and the subsequent
iPrEx open label extension (OLE), as well as analyses of
depression, other co-morbidities, and adherence are cur-
rently underway.
CSA is a traumatic early life event that adversely
influences psychological and physical health in addition to
socioeconomic well-being [41, 42]. CSA has been shown
to be an important correlate of sexual risk-taking behaviors
and HIV infection [15, 16]. CASI questions related to
sexual debut may be relevant to assessing CSA; underage
and forced sexual experience with an adult has been
defined as CSA [15]. There is an association between
having reported being ‘‘manipulated’’ or ‘‘forced’’ at anal
sex debut and higher CES-D scores and increased likeli-
hood of reporting suicidal ideation in the iPrEx cohort. The
clinical significance of the observed 3-point average dif-
ference on CES-D scores is unclear. This relatively small
difference seen on the CES-D may suggest that the influ-
ence of CSA on sexual behavior is mediated by other social
and psychological variables, and not necessarily by
depression [16, 43]. We did not see any association with
any other questions pertaining to possible traumatic expe-
riences; however these questions were not instruments
specifically designed to screen for such events.
There were more frequent reports of ncRAI among those
in the highest quartile of CES-D scores. This finding is
consistent with previous studies showing depression to be
associated with sexual practices that can increase acquisition
of HIV infection [14, 33, 44]. Having more depressive
symptoms may put the person at higher risk for acquiring
HIV during sex, possibly because depression may undermine
self-care, communication with partners, or perception of
risk. Depression may interfere with discussions about con-
dom use, and asserting a desire for protective use of con-
doms. In addition, depression may trigger use of substances,
which could impair perceptions of risk or impulse control.
During iPrEx, three participants on the FTC/TDF arm
seroconverted while on a protocol-required study drug
interruption triggered by depression-related AEs. Several
findings support a recommendation to continue PrEP during
periods of depression. We saw no evidence that PrEP was
less efficacious among participants having a CES-D score
above 16 during the iPrEx trial (Mantel–Haenszel test for
heterogeneity p = 0.92). There was no link between oral
FTC/TDF PrEP and depression or depressive symptoms.
Behavior linked to HIV risk was more commonly reported
among people with depressive symptoms. Indeed, 3 HIV
infections occurred during protocol mandated interruptions
in study medication due to depression. The protocol
requirement to stop PrEP during periods of depression was
amended as the iPrEx trial transitioned from the randomized
phase to OLE, based on the findings reported here. In the
iPrEx OLE study, drug was only interrupted if participants
reported suicidal ideation with a concrete plan.
Adherence to HIV treatment can be affected by
depression [5, 45, 46]. Given the blinded placebo-con-
trolled design of the iPrEx trial and the protocol require-
ment that study medication be stopped in participants with
grade 4 depression AEs, the analysis of adherence to PrEP
amongst depressed people during the randomized phase of
iPrEx is difficult and subject to bias. However, analyses
from iPrEx OLE examining the role of depression on
adherence to open-label PrEP are currently underway.
Table 4 CES-D scores and non-condom Receptive Anal Intercourse
(ncRAI) in iPrEx participants
Odds of having reported ncRAI
CESD Quartile Odds ratioa 95 % CI
0–7 ref
8–12 1.17 (0.88, 1.57)
13–19 1.21 (0.90, 1.61)
20 and above 1.46 (1.09, 1.94)
Wald test for linearity p = 0.012
Sexual practices data was collected at the same time the CES-D
questionnaire was administered and reflects behavior over the prior
3 months. ncRAI is considered positive if a participant reports any
instance of non-condom receptive anal intercourse during the inter-
view-administered questionnaire
a Mixed level logistic regression using the first available CES-D
score and corresponding reported sexual practices. Random effects
for site were included. Analysis was controlled for number of part-
ners, age of participant, and anti-depressant medication use
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Because iPrEx was conducted at 11 study sites across the
globe, our analyses are somewhat limited by a wide variation
in the cultural context, access to mental health services, and
access to anti-depressant medications. Studies of depression
in the Hispanic Health and Nutrition Examination Survey
(HHANES) using CES-D scales suggest that results may
need to be interpreted differently in Hispanic populations
[47–49]. Though validated in Spanish, Thai, and Portuguese,
CES-D scores and their clinical significance should be
interpreted carefully cross-culturally. This limitation was
partially addressed by analyzing the CES-D scores as con-
tinuous variables or divided into quartiles, and controlling
analyses for random effects by study site.
Use of anti-depressants was low overall (8 % of entire
cohort), being reported in only one half of people with
depression-related AEs grade 2 or higher. Anti-depressant
medication use varied dramatically by site (but not by
study arm), with study sites in the USA reporting the
highest proportions of psychotropic medication use. Anti-
depressant medication use had no effect on our study
findings. No drug interactions are expected between FTC/
TDF and commonly used anti-depressant medications [50].
Individuals who are under care for depression should be
evaluated for PrEP indications. In settings having a sub-
stantial prevalence of HIV infection, PrEP indications
include inconsistent condom use outside of mutually
monogamous relationship with a recently tested HIV-neg-
ative partner, any sexual partner who is HIV-positive or
whose HIV status is unknown, any sexually transmitted
infection by self-report or laboratory testing, use of post-
exposure prophylaxis, or any sharing of needles for injec-
tion drug use [51]. Antidepressant therapy may improve
PrEP adherence and uptake, as it has for antiretroviral
therapy for HIV infection (reviewed in [52]).
A limitation of the current analysis is that plans to
examine depression symptoms systematically using CES-D
and the suicidal ideation screener were made after the trial
was already underway, and were triggered in part by the
high rates of depression-related AEs (depression AEs were
evaluated throughout the entire study follow-up and
therefore do not suffer from this same limitation). Although
15 % of participants never completed a CES-D, the
available information this was evenly distributed across the
FTC/TDF and placebo arms. Furthermore, CES-D scores,
when available, did not predict earlier study drop out after
controlling for age and study site. Additionally, when
examining pre-existing conditions of depression that were
recorded for all study participants, we see no difference in
frequency of pre-existing conditions in participants who
never received a CES-D versus those who did. These
findings suggest that our finding that depressive symptoms
were not associated with oral FTC/TDF PrEP is not likely
to be substantially biased by missing CES-D scores.
Oral FTC/TDF PrEP does not affect depression incidence
or severity and depressive symptoms are associated with
sexual practices that increase risk for HIV acquisition. The
additional protection conferred by PrEP could avert infec-
tions during these especially vulnerable times, while fos-
tering engagement in health services. Adherence to PrEP and
other safer sex recommendations may be especially chal-
lenging during periods of depression, so specific attention to
promoting adherence during these periods is important.
Given the high prevalence of depression and HIV incidence
among MSM/TGW, especially young people, PrEP services
should include screening and management of trauma,
including CSA. PrEP programs may provide infrastructure
for increasing access to mental health services, enabling
synergistic diagnoses, and management of co-morbidities.
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